Terence Flynn
Stock Analyst at Morgan Stanley
(4.08)
# 580
Out of 4,761 analysts
171
Total ratings
58.51%
Success rate
10.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Maintains: Overweight | $36 → $25 | $11.07 | +125.84% | 5 | Feb 18, 2025 | |
| OGN Organon & Co. | Maintains: Equal-Weight | $17 → $16 | $15.49 | +3.29% | 8 | Feb 14, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Underweight | $30 → $32 | $47.91 | -33.21% | 7 | Feb 14, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $113 → $106 | $89.50 | +18.44% | 16 | Feb 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $224 → $239 | $202.08 | +18.27% | 14 | Feb 3, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $16 → $17 | $16.87 | +0.77% | 4 | Feb 3, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Equal-Weight | $56 → $11 | $12.17 | -9.61% | 5 | Jan 27, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $175 → $163 | $162.30 | +0.43% | 19 | Jan 23, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $39 | $55.83 | -30.15% | 10 | Nov 12, 2024 | |
| BNTX BioNTech SE | Upgrades: Overweight | $93 → $145 | $120.01 | +20.82% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $23.77 | +396.53% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $1,106 | $873.68 | +26.59% | 18 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $36.91 | +57.14% | 1 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $5.17 | +596.32% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $51 | $33.42 | +52.60% | 11 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $310 → $303 | $303.01 | -0.00% | 5 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $310 → $321 | $361.10 | -11.10% | 8 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $121 → $168 | $92.25 | +82.11% | 6 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $29 | $26.30 | +10.27% | 13 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $3.01 | +165.78% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $20 | $17.77 | +12.55% | 7 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $140.64 | +210.01% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $250.59 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.71 | - | 1 | Jul 21, 2017 |
Arcus Biosciences
Feb 18, 2025
Maintains: Overweight
Price Target: $36 → $25
Current: $11.07
Upside: +125.84%
Organon & Co.
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $15.49
Upside: +3.29%
CRISPR Therapeutics AG
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $47.91
Upside: -33.21%
Merck & Co.
Feb 5, 2025
Maintains: Equal-Weight
Price Target: $113 → $106
Current: $89.50
Upside: +18.44%
AbbVie
Feb 3, 2025
Maintains: Overweight
Price Target: $224 → $239
Current: $202.08
Upside: +18.27%
Nurix Therapeutics
Feb 3, 2025
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.87
Upside: +0.77%
Intellia Therapeutics
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $12.17
Upside: -9.61%
Johnson & Johnson
Jan 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $163
Current: $162.30
Upside: +0.43%
Bristol-Myers Squibb Company
Nov 12, 2024
Maintains: Underweight
Price Target: $36 → $39
Current: $55.83
Upside: -30.15%
BioNTech SE
Sep 24, 2024
Upgrades: Overweight
Price Target: $93 → $145
Current: $120.01
Upside: +20.82%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $23.77
Upside: +396.53%
Aug 27, 2024
Reiterates: Overweight
Price Target: $1,106
Current: $873.68
Upside: +26.59%
Jul 24, 2024
Initiates: Overweight
Price Target: $58
Current: $36.91
Upside: +57.14%
Jul 23, 2024
Initiates: Overweight
Price Target: $36
Current: $5.17
Upside: +596.32%
Jul 11, 2024
Maintains: Overweight
Price Target: $48 → $51
Current: $33.42
Upside: +52.60%
Jul 11, 2024
Maintains: Equal-Weight
Price Target: $310 → $303
Current: $303.01
Upside: -0.00%
Jul 11, 2024
Downgrades: Equal-Weight
Price Target: $310 → $321
Current: $361.10
Upside: -11.10%
May 6, 2024
Maintains: Buy
Price Target: $121 → $168
Current: $92.25
Upside: +82.11%
May 2, 2024
Maintains: Equal-Weight
Price Target: $28 → $29
Current: $26.30
Upside: +10.27%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $3.01
Upside: +165.78%
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $32 → $20
Current: $17.77
Upside: +12.55%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $140.64
Upside: +210.01%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $250.59
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $0.71
Upside: -